Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2023-01-09 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1938 characters) and contains the header 'RNS Number : 1090M' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement made via the regulatory news service. Since it is a direct, short announcement disseminated through the RNS system and does not fit into specific financial reporting categories (like 10-K, ER, IR), it falls best under the general Regulatory Filings category (RNS) or potentially a specific operational announcement if one existed. Given the provided definitions, RNS is the most appropriate general regulatory announcement category for this type of market notice.
2023-01-09 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1921 characters) and contains the header 'RNS Number : 1082M' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading mechanics, not a comprehensive financial report or a standard regulatory filing like a 10-K or ER. Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIV, DIRS, or ER), the most appropriate fallback category is Regulatory Filings (RNS).
2023-01-09 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half year Report' for Fusion Antibodies plc, covering the six months ended 30 September 2022. It contains detailed financial highlights, operational reviews, a condensed statement of comprehensive income, and a statement of directors' responsibilities. As it provides comprehensive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2023
2022-12-05 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by the RNS Number and the footer referencing RNS/LSE). The core content announces two things: 1) The date for the release of the 'unaudited interim results' (which would typically be an IR document), and 2) The scheduling of an 'Investor presentation' related to those results. Since the document itself is not the full interim report (IR) or the presentation (IP), but rather an announcement about the timing of these future events and the hosting of a presentation/Q&A session, it fits best under the category of announcing the publication or availability of company information. The document explicitly states 'Notice of results' and details the upcoming investor presentation. This aligns most closely with the Report Publication Announcement (RPA) category, which covers announcements regarding the timing or release of company reports, or the general Regulatory Filings (RNS) category. Given the specific nature of announcing the release date of results and the associated investor event, RPA is a strong fit, but RNS is the general regulatory announcement wrapper. Since the primary action is announcing the upcoming release of results and a related presentation, RPA is more specific than the general RNS fallback. However, the document also contains details about the presentation itself (date, CEO/CFO attending, Q&A mechanism), which leans towards Investor Presentation (IP) material being announced. Given the structure, it is primarily a notice about future events and report releases. Let's re-evaluate the definitions. It announces the *release* of interim results (IR) and an *investor presentation* (IP). Since it is a notice *about* these events rather than the full content of the IR or IP, RPA (Report Publication Announcement) is appropriate for announcing the results release date. However, the focus on the upcoming investor presentation/Q&A session also strongly suggests Investor Presentation (IP) context, even if it's just the invitation. Given the document's brevity (5505 chars) and its function as a notice of future events/releases, RPA is the most accurate classification for the announcement itself.
2022-11-24 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification filed via RNS (RNS Number: 7756E) dated October 31, 2022. The content explicitly details a 'Director/PDMR Shareholding' transaction, specifically the purchase of ordinary shares by a Non-Executive Director (Sonya Ferguson). This directly matches the definition of 'Director's Dealing' (insider trades by executives/directors). Therefore, the appropriate filing type code is DIRS.
2022-10-31 English
Block admission six monthly return
Remuneration Information Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange's news service. The content is a 'Block admission six monthly return' detailing the status of employee share options over a specific period (April 2, 2022, to October 1, 2022). This type of routine regulatory update, which doesn't fit neatly into specific financial reports (10-K, IR, ER) or corporate actions (DIV, SHA), is best classified under the general regulatory announcement category. Although it contains specific data, it is a formal regulatory filing notification rather than a comprehensive report or a simple announcement of a report's publication. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of routine compliance disclosure that is not covered by other specific codes like DIRS or SHA.
2022-10-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.